




LUNG CANCER **UPDATES**

AACR HIGHLIGHTS

29 MARZO - 3 ABRIL 2019



ATLANTA

Iniciativa científica de:



Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group



ATLANTA

EC KeyNote 189: Análisis de los pacientes con M1 hepáticas o cerebrales tratados con pembrolizumab + platino + pemetrexed

Dr. Juan Felipe Córdoba

Iniciativa científica de:



Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

Outcomes Among Patients With Metastatic Nonsquamous NSCLC With Liver Metastases or Brain Metastases Treated With Pembrolizumab Plus Pemetrexed-Platinum: Results From the KEYNOTE-189 Study

Marina C. Garassino, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Giovanna Speranza, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J. Hochmair, Steven F. Powell, Susanna Y.-S. Cheng, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Belén Rubio-Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E. Gray, Anna Cardellino, Jing Yang, M. Catherine Pietanza, Delvys Rodríguez-Abreu

Baseline Characteristics

	Pembro + Pem + Platinum (N = 410)	Placebo + Pem + Platinum (N = 206)
Age, median (range), years	65.0 (34–84)	63.5 (34–84)
Men	254 (62)	109 (53)
ECOG PS 1	220 (54)	125 (61)
Liver metastases ^a	66 (16)	49 (24)
Stable brain metastases ^a	73 (18)	35 (17)
Previously treated	43 (10)	23 (11)
Former/current smoker	362 (88)	181 (88)
PD-L1 TPS ≥1%	260 (63)	128 (62)
Carboplatin chosen	297 (72)	148 (72)
Prior thoracic radiation	29 (7)	19 (9)
Prior neoadjuvant therapy	5 (1)	6 (3)
Prior adjuvant therapy	25 (6)	14 (7)

Data are shown as n (%) unless otherwise specified.
^a25 patients had both brain and liver metastases.
 Data cutoff date: September 21, 2018.

Iniciativa científica de:




Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

Overall Survival: Liver Metastases

With Liver Metastases


	Events, n (%)	HR (95% CI)
Pembro/Pem/Plat	43 (65.2)	0.62
Placebo/Pem/Plat	41 (83.7)	(0.39–0.98)



No. at risk	0	3	6	9	12	15	18	21	24	27	30	33
Pembro/ Pem/Plat	86	52	45	39	33	28	27	16	5	2	1	0
Placebo/ Pem/Plat	49	40	26	16	15	12	11	7	4	0	0	0

Without Liver Metastases

	Events, n (%)	HR (95% CI)
Pembro/Pem/Plat	170 (49.4)	0.58
Placebo/Pem/Plat	103 (65.6)	(0.45–0.74)



No. at risk	0	3	6	9	12	15	18	21	24	27	30	33
Pembro/ Pem/Plat	344	325	301	277	250	228	207	128	74	26	1	0
Placebo/ Pem/Plat	157	143	123	99	84	70	61	38	22	10	0	0

Data cutoff date: September 21, 2018

Iniciativa científica de:




Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

Overall Survival: Brain Metastases

With Brain Metastases


	Events, n (%)	HR (95% CI)
Pembro/Pem/Plat	42 (57.5)	0.41
Placebo/Pem/Plat	28 (80.0)	(0.24–0.67)



No. at risk	0	3	6	9	12	15	18	21	24	27	30	33
Pembro/ Pem/Plat	73	66	61	52	47	45	38	25	14	5	0	0
Placebo/ Pem/Plat	35	27	21	15	12	10	8	5	3	1	0	0

Without Brain Metastases

	Events, n (%)	HR (95% CI)
Pembro/Pem/Plat	171 (50.7)	0.59
Placebo/Pem/Plat	116 (67.8)	(0.46–0.75)



No. at risk	0	3	6	9	12	15	18	21	24	27	30	33
Pembro/ Pem/Plat	337	311	285	264	236	211	196	119	65	23	2	0
Placebo/ Pem/Plat	171	156	128	100	87	72	64	40	23	9	0	0



Data cutoff date: September 21, 2018.

Iniciativa científica de:



Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group

All Cause Adverse Events: Frequency $\geq 20\%$



Data cutoff date: September 21, 2018.

Iniciativa científica de:



Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group